These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18366993)

  • 1. Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment.
    Perkins JM; Davis SN
    Curr Diab Rep; 2008 Feb; 8(1):12-9. PubMed ID: 18366993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endocannabinoid system: a promising novel mechanistic pathway in the cardiometabolic syndrome.
    Al-Jaghbeer E; Khraisat A; Singh SP
    J Cardiometab Syndr; 2008; 3(1):40-4. PubMed ID: 18326971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endocannabinoid system as a novel approach for managing obesity.
    Lillo JL
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endocannabinoid system and the control of glucose homeostasis.
    Nogueiras R; Rohner-Jeanrenaud F; Woods SC; Tschöp MH
    J Neuroendocrinol; 2008 May; 20 Suppl 1():147-51. PubMed ID: 18426514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
    Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
    Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.
    Mach F; Montecucco F; Steffens S
    Pharmacol Rep; 2009; 61(1):13-21. PubMed ID: 19307689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Impact of endocannabinoid system in modulation of cardiometabolic risk factors].
    Sulcová A
    Vnitr Lek; 2006 Jun; 52(6):615-8. PubMed ID: 16871766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.
    Dibble CT; Gelfand EV; Cannon CP
    Curr Atheroscler Rep; 2007 Nov; 9(5):359-66. PubMed ID: 18001618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the endocannabinoid system in energy balance regulation and obesity.
    Cota D
    Front Horm Res; 2008; 36():135-145. PubMed ID: 18230900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk.
    Rosenson RS
    Cardiology; 2009; 114(3):212-25. PubMed ID: 19641317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation.
    Tucci SA; Halford JC; Harrold JA; Kirkham TC
    Curr Med Chem; 2006; 13(22):2669-80. PubMed ID: 17017918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
    Cota D; Sandoval DA; Olivieri M; Prodi E; D'Alessio DA; Woods SC; Seeley RJ; Obici S
    Obesity (Silver Spring); 2009 Aug; 17(8):1641-5. PubMed ID: 19325539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis.
    O'Hare JD; Zielinski E; Cheng B; Scherer T; Buettner C
    Diabetes; 2011 Apr; 60(4):1055-62. PubMed ID: 21447652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction.
    Woods SC
    JAAPA; 2007 Nov; Suppl Endocannabinoid():7-10. PubMed ID: 18047036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The endocannabinoid system: a new paradigm in the metabolic syndrome treatment].
    de Godoy-Matos AF; Guedes EP; de Souza LL; Valério CM
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):390-9. PubMed ID: 16767305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenge of treating obesity: the endocannabinoid system as a potential target.
    Isoldi KK; Aronne LJ
    J Am Diet Assoc; 2008 May; 108(5):823-31. PubMed ID: 18442506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing cardiometabolic risk through selective antagonism of CB1 receptors.
    Van Gaal L
    Clin Cornerstone; 2007; 8 Suppl 6():S24-9. PubMed ID: 17948364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.
    Silvestri C; Di Marzo V
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1309-22. PubMed ID: 22780328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.